Management
Timothy M. Mayleben
Chief Executive Officer, President, and Director
Tim joined Aastrom as a member of the company’s board of directors in June 2005. Previously he was an advisor to life science and healthcare companies through his advisory and investment firm, ElMa Advisors. He has also been president, chief operating officer and a director of NightHawk Radiology Holdings, Inc. Tim also served as chief operating officer of Esperion Therapeutics, where he led the raising of more than $200 million in venture capital and institutional equity funding and later negotiated the acquisition of Esperion by Pfizer in February 2004. Tim is on the advisory board of the Wolverine Venture Fund and serves as a director for several private life science companies. He holds an MBA with distinction from the J.L. Kellogg Graduate School of Management at Northwestern University and a BA in business administration from the University of Michigan Ross Business School.
Ronnda L. Bartel, PhD
Chief Scientific Officer
Ronnda joined Aastrom in 2006 and is responsible for the scientific direction of the company, including research, development and technical operations. She has more than 20 years of research and product development experience and most recently was executive director, biological research at MicroIslet and vice president, scientific development at StemCells Inc. Earlier in her career, she was senior principal scientist and director of research at Advanced Tissue Sciences and was involved in the development and approval of some of the first cell-based products approved by the FDA. She has also worked as senior director, science and technology at SRS Capital, LLC evaluating life science investments and has held positions in clinical development, drug delivery, business development and manufacturing. Ronnda holds a PhD in biochemistry from the University of Kansas, has completed postdoctoral work at the University of Michigan and received a BA in chemistry and biology from Tabor College.
Sharon M. Watling, PharmD
Vice President, Clinical Development
Sharon joined Aastrom in February 2010 and is responsible for clinical development, clinical operations and regulatory affairs. She has over 12 years of experience in clinical development, with an emphasis on translational science, clinical development and clinical strategies. Her industry career started in late- stage development within Warner-Lambert/Parke Davis and evolved while at Pfizer to include an early clinical leadership role in cardiovascular-metabolic diseases. Following Pfizer, she was site leader and senior director, clinical development at Metabasis, Inc. Most recently, she served as the research and development strategy leader at Cognigen Corporation, working with multiple companies to incorporate modeling and simulation practices into their development strategies. Prior to industry, she was an intensive care unit clinical specialist at various academic institutions. Sharon holds a PharmD from the University of Michigan College of Pharmacy.
Brian D. Gibson
Vice President, Finance
Brian joined Aastrom in July 2010 and brings more than 11 years of finance and accounting experience to Aastrom. Prior to joining Aastrom, Brian was a senior manager at PricewaterhouseCoopers where his skills were applied in multiple industries, including life sciences and healthcare. Brian holds a BA in accounting with high honor from the Eli Broad College of Business at Michigan State University and is a certified public accountant.
Tod Borton
Vice President, Technical Operations
Tod Borton joined Aastrom in July of 2006 and has more than 25 years of product development and quality experience in the domestic, international, biotechnology and medical device industries. Prior to joining Aastrom, Tod held the position of director of quality at Terumo Cardiovascular where he was responsible for quality assurance, document control, and sustaining engineering. Prior to Terumo he held the position of vice president, new product development and advanced engineering at Pall Corporation where he developed and commercialized many biotech and medical filtration devices. Tod has authored many patents in the area of biotechnology and medical filtration device technologies and received a B.S. in plastic technology from Eastern Michigan University.